MYCN gain and MYCN amplification in a stage 4S neuroblastoma

Cancer Genet Cytogenet. 2003 Jan 15;140(2):157-61. doi: 10.1016/s0165-4608(02)00677-5.

Abstract

Stage 4S neuroblastoma is a disease associated with spontaneous regression and good survival. We present a patient whose evolution has shown the variety and complexity of this disease in infants. Biologic factors, such as ploidy, MYCN copy number, loss of 1p36, and other chromosomal gains and losses were determined. A complex pattern of genetic abnormalities, such as near-diploidy, MYCN gain (2-4 copies per haploid genome) and imbalance/deletion of 1p36 was seen in the diagnostic sample. An extensive disseminated disease after a latent period of 26 months was associated with a special genetic evolution, such a tetraploidy, MYCN amplification (2:100-500 copies), 1p36 deletion, and gain of 17q. Our results provide evidence that either the primary tumor was heterogeneous in terms of gene amplification or that amplification was acquired later on as a transition from MYCN gain. We suggest that near-di-/tetraploid 4S tumors with MYCN gain and/or deletion 1p could be progressing 4S tumors.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Gland Neoplasms / genetics*
  • Adrenal Gland Neoplasms / pathology
  • Aneuploidy
  • Chromosome Deletion
  • Chromosomes, Human, Pair 1 / genetics
  • Chromosomes, Human, Pair 17 / genetics
  • Disease Progression
  • Fatal Outcome
  • Female
  • Gene Amplification*
  • Genes, myc*
  • Humans
  • Infant
  • Neoplasm Staging
  • Neuroblastoma / genetics*
  • Neuroblastoma / pathology